🚀 VC round data is live in beta, check it out!
Susmed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Susmed and similar public comparables like Revium Recovery, Rapid Micro Biosystems, C-Rad, Neuronetics and more.
Susmed Overview
About Susmed
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
Founded
2015
HQ
Employees
39
Website
Financials (LTM)
EV
$77M
Susmed Financials
Susmed reported last 12-month revenue of $5M.
In the same LTM period, Susmed generated had net loss of ($1M).
Revenue (LTM)
Susmed P&L
In the most recent fiscal year, Susmed reported revenue of $3M and EBITDA of ($2M).
Susmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5M | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $3M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 91% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (59%) | XXX | XXX | XXX |
| EBIT Margin | (30%) | XXX | (60%) | XXX | XXX | XXX |
| Net Profit | ($1M) | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | (30%) | XXX | (60%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Susmed Stock Performance
Susmed has current market cap of $102M, and enterprise value of $77M.
Market Cap Evolution
Susmed's stock price is $6.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $77M | $102M | 0.3% | XXX | XXX | XXX | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSusmed Valuation Multiples
Susmed trades at 16.8x EV/Revenue multiple, and (41.7x) EV/EBITDA.
EV / Revenue (LTM)
Susmed Financial Valuation Multiples
As of April 20, 2026, Susmed has market cap of $102M and EV of $77M.
Equity research analysts estimate Susmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Susmed has a P/E ratio of (75.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV (current) | $77M | XXX | $77M | XXX | XXX | XXX |
| EV/Revenue | 16.8x | XXX | 24.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (41.7x) | XXX | XXX | XXX |
| EV/EBIT | (56.5x) | XXX | (40.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 26.9x | XXX | XXX | XXX |
| P/E | (75.3x) | XXX | (54.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (26.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Susmed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Susmed Margins & Growth Rates
Susmed's revenue in the last 12 month grew by 167%.
Susmed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Susmed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 167% | XXX | 57% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (59%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (10%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 96% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 55% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 152% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Susmed Public Comps
See public comps and valuation multiples for other Healthcare Software and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Susmed | XXX | XXX | XXX | XXX | XXX | XXX |
| Revium Recovery | XXX | XXX | XXX | XXX | XXX | XXX |
| Rapid Micro Biosystems | XXX | XXX | XXX | XXX | XXX | XXX |
| C-Rad | XXX | XXX | XXX | XXX | XXX | XXX |
| Neuronetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Health In Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Susmed M&A Activity
Susmed acquired XXX companies to date.
Last acquisition by Susmed was on XXXXXXXX, XXXXX. Susmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Susmed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSusmed Investment Activity
Susmed invested in XXX companies to date.
Susmed made its latest investment on XXXXXXXX, XXXXX. Susmed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Susmed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Susmed
| When was Susmed founded? | Susmed was founded in 2015. |
| Where is Susmed headquartered? | Susmed is headquartered in Japan. |
| How many employees does Susmed have? | As of today, Susmed has over 39 employees. |
| Is Susmed publicly listed? | Yes, Susmed is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Susmed? | Susmed trades under 4263 ticker. |
| When did Susmed go public? | Susmed went public in 2021. |
| Who are competitors of Susmed? | Susmed main competitors are Revium Recovery, Rapid Micro Biosystems, C-Rad, Neuronetics. |
| What is the current market cap of Susmed? | Susmed's current market cap is $102M. |
| What is the current revenue of Susmed? | Susmed's last 12 months revenue is $5M. |
| What is the current revenue growth of Susmed? | Susmed revenue growth (NTM/LTM) is 167%. |
| What is the current EV/Revenue multiple of Susmed? | Current revenue multiple of Susmed is 16.8x. |
| Is Susmed profitable? | No, Susmed is not profitable. |
| What is the current net income of Susmed? | Susmed's last 12 months net income is ($1M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.